A single-center retrospective cohort study to evaluate antiviral effectiveness of Entecavir/Adefovir combination therapy in patients with multiple suboptimal response

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-12002285

Enrollment

Unknown

Registered

2012-06-15

Start date

2012-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

group:ETV+ADV

Eligibility

Sex/Gender

All

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Detectable HBsAg >24 weeks; 2. suboptimal or failure patients with sequential monotherapy or combo with multiple Nuc (definition: sequential monotherapy or combo with other NUc after more than 6 ms with HBV DNA>103 copies/ml, exclusion for compliance); 3. treated with ADV plus ETV (dosage 0.5mg/1.0mg daily); 4. Age >16 years old.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or breastfeeding are excluded; 2. Co-infection with HIV, HCV, HDV are excluded.

Design outcomes

Secondary

Measure	Time frame
blood calcium;phosphorum;	—

Primary

Measure	Time frame
HBV DNA level;HBeAg seroconversion;ALT;creatinine;creatine kinase;	—

Countries

China

Contacts

Public ContactXiaohong Wang

wangxhke@126.com+86 13908311987

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026